Last reviewed · How we verify

NCT05464550: RFASD

Role of Self-focused Attention in Depression

Completed NA Last updated 24 May 2023
What this trial tests

NA trial testing Eye tracker in Depression in 30 participants. Completed in 16 June 2022.

Timeline
8 December 2021
Primary endpoint
15 June 2022
16 June 2022

Quick facts

Lead sponsorCentre Hospitalier Henri Laborit
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment30
Start date8 December 2021
Primary completion15 June 2022
Estimated completion16 June 2022
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Henri Laborit

Who can join

Adults 18 to 60, any sex, with Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Using a task measuring the tracking of eye movements, the aim of this study is to demonstrate that individuals suffering from depression focus their attention more on their reflection in the screen after recalling a failure (and this all the more so as their depressive symptomatology is strong) .

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Eye tracker

Trials testing the same drug.

Other recruiting trials for Depression

Currently open trials in the same condition.

Other Centre Hospitalier Henri Laborit trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05464550.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing